Research programme: monoclonal antibodies - Medarex/MGI Pharma Biologics
Latest Information Update: 12 Mar 2008
At a glance
- Originator Medarex; MGI Pharma Biologics
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 May 2007 No development reported - Preclinical for Cancer in USA (unspecified route)
- 29 Jun 2005 This programme is still in active development
- 31 Dec 2004 ZYCOS has been acquired by MGI Pharma and is now called MGI Pharma Biologics